Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

OGT launches NGS SureSeq Myeloid MRD panel

February 2025—OGT announced the North American launch of its next-generation sequencing SureSeq Myeloid MRD panel. The ultra-sensitive panel enables the detection of 13 key measurable residual disease–associated biomarkers in acute myeloid leukemia. Ultralow variant detection, including for very large FLT3-ITDs, enables a stronger characterization of a sample’s current AML status. The company’s complimentary NGS analysis software, Interpret, is available on the cloud or as a local install and provides a powerful bioinformatic analysis pipeline.

Qiagen EZ2 Connect reaches milestone of more than 1,000 placements

February 2025—Qiagen announced it has reached a milestone of having more than 1,000 placements of the EZ2 Connect automated sample preparation instrument. Launched in 2021, the EZ2 Connect is designed to automate the entire process of nucleic acid purification, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility. The company says the system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing.

BioMérieux acquires immunoassay start-up SpinChip

February 2025—BioMérieux has entered into an agreement to acquire SpinChip Diagnostics (Oslo, Norway), a privately held company that has developed an immunoassay diagnostics platform that can deliver results from a whole blood sample within 10 minutes. SpinChip is initially developing lab-quality tests to address indications common in acute care settings, such as myocardial infarction, and will first focus on high-sensitive troponin I, NT-proBNP, and D-dimer.

Beckman Coulter RUO assays for neurodegenerative diseases

February 2025—Beckman Coulter Diagnostics announced the availability of research use only blood-based biomarker immunoassays intended to assess phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, and apolipoprotein ε4 biomarkers. These neurogenerative RUO assays are available for use on the DxI 9000 immunoassay analyzer. The GFAP, NfL, and APOE ε4 assays are also available for use on the Access 2 immunoassay analyzer.

Adaptive, NeoGenomics sign multiyear collaboration

February 2025—Adaptive Biotechnologies Corp. and NeoGenomics announced a multiyear exclusive strategic commercial collaboration that aims to advance minimal residual disease monitoring options for patients with select blood cancers.

Genomadix gets Health Canada license for Cube CYP2C19 system

Februrary 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test. The test can be used to aid clinicians in determining a therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The Genomadix Cube CYP2C19 system identifies the CYP2C19 *2, *3, and *17 alleles directly from buccal swabs in about an hour.

Verichem reference materials for acetaminophen, salicylate

February 2025—Verichem Laboratories has announced the availability of multilevel clinical reference materials intended for the calibration and calibration verification of acetaminophen and salicylate assays on a wide array of diagnostic testing systems. The materials come in a ready-to-use, liquid-stable format that incorporates the serum-like reactivity of a protein-based matrix with the gravimetric accuracy of an absolute standard. The kit contains 5.0 mL of material at six concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains ethanol and lactate to determine the calibration verification of these assays.

FDA grants breakthrough designation to Beckman Coulter Alzheimer’s test

February 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio. The blood test measures the ratio of phosphorylated tau protein (pTau217) to beta‑amyloid 1-42, two key biomarkers implicated in the neurodegenerative processes of Alzheimer’s disease. A blood-based IVD test that can quantify these biomarkers in plasma could provide a noninvasive, accessible, and earlier method of detecting Alzheimer’s-related pathology, potentially before clinical symptoms manifest, the company said in a statement.

Qiagen launches QIAcuityDx dPCR system

January 2025—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow. The nanoplate-based workflow disperses a sample into thousands of tiny partitions and then reads reactions simultaneously to quantify signals from DNA and RNA.

MARKETPLACE

TRENDING